Year All20242023202220212020201920182017201620152014 Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024 Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 1, 2024 Corcept Completes Enrollment in Phase 4 CATALYST Trial April 29, 2024 Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024 Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024 Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024 Corcept Completes Enrollment in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 8, 2024 Corcept Completes Enrollment in Phase 3 GRADIENT Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 1, 2024 Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update February 15, 2024 Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial February 15, 2024
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 1, 2024
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024
Corcept Completes Enrollment in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 8, 2024
Corcept Completes Enrollment in Phase 3 GRADIENT Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 1, 2024
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update February 15, 2024
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial February 15, 2024
